Volume : 11, Issue : 01, January – 2024

Title:

A CLINICALLY SIGNIFICANT DRUG – DRUG INTERACTIONS IN PSYCHIATRY

Authors :

*Honey.E, *Heena.S

Abstract :

Patients with psychiatry are often exposed drug-drug interactions, the main aim of the study is to investigate the drug interactions in the psychiatric patients. Most clinically significant drug interactions are pharmacodynamic (PD) and pharmacokinetic (PK) that results in augmented or antagonistic actions at a receptor. In metabolism, the major enzymes which are involved in drug interactions of psychotropic drugs are Cytochrome P450 (CYP) System. Drug-drug interactions are said to play a Significant and important role in the occurrence of adverse drug reactions. The major drug interactions in psychiatry are caused by haloperidol, clozapine, olanzapine, amitriptyline, amisulpride etc.. Concurrent use of these drugs can increase in QT prolongation and increase in the risk of Ventricular anthymias. The main aim of this study is to describe the drug interactions that causes major effects in psychiatric patients.
KEY WORDS: Olanzapine, haloperidol, amitryptaline, sertralin

Cite This Article:

Please cite this article in press E.Honey et al A Clinically Significant Drug – Drug Interactions In Psychiatry., Indo Am. J. P. Sci, 2024; 11 (01).

Number of Downloads : 10

References:

1) Mahr GC, Berchou R, Balon R. A grand mal seizure associated with desipramine and haloperidol. Can J Psychiatry. 1987;32:463-4.
2) Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K. Doxepin induced torsade de pointes. Pacing Clin Electrophysiol. 1982;5:873-7.
3) Gram LF, Overo KF. Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J. 1972;1:463-5
4) Zelman S, Guillan R. Heat stroke in phenothiazine-treated patients: a report of three fatalities. Am J Psychiatry. 1970;126:1787-90.
5) Mann SC, Boger WP. Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated. Am J Psychiatry. 1978;135:1097-100.
6) Warnes H, Lehmann HE, Ban TA. Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases. Can Med Assoc J. 1967;96:1112-3.
7) Product Information. Zyprexa (olanzapine). Lilly, Eli and Company. 2001.
8) Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry. 2005;66:1614-1615.
9) Naso AR. Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines. Am J Health Syst Pharm. 2008;65:1180-3.
10) Hamilton MJ, Bush M, Smith P, Peck AW. The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man. Br J Clin Pharmacol. 1982;14:791-7.
11) Stambaugh JE, Lane C. Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination. Cancer Invest. 1983;1:111-7.
12) Sotaniemi EA, Anttila M, Rautio A, et al. Propranolol and sotalol metabolism after a drinking party. Clin Pharmacol Ther. 1981;29:705-10.
13) Product Information. Lexapro (escitalopram). Forest Pharmaceuticals. 2002. Cerner Multum, Inc. UK Summary of Product Characteristics.
14) CanadianPharmacistsAssociatione-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink 2006.
15) Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc. 2020.
16) Muller N, Brockmoller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele: a slowly reversible interaction with fluoxetine. Ther Drug Monit. 1991;13:533-6.
17) Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239-48.
18) Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993;53:84-8.
19) Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003;42:1227-33.
20) Product Information. Tegretol (carbamazepine). Novartis Pharmaceuticals. 2002.
21) Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol. 1997;17:107-9.
22) Cerner Multum, Inc. UK Summary of Product Characteristics.
23) Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-13.
24) Product Information. Zoloft (sertraline). Roerig Division. 2001.
25) Product Information. Prozac (fluoxetine). Dista Products Company. 2001.
26) Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-4.
27) Product Information. Zyprexa (olanzapine). Lilly, Eli and Company. 2001.
28) Markowitz JS, DeVane CL. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration. J Clin Psychopharmacol. 1999;19:289-91.
29) Muller N, Brockmoller J, Roots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele: a slowly reversible interaction with fluoxetine. Ther Drug Monit. 1991;13:533-6.
30) Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239-48.
31) Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993;53:84-8.
32) Dhillon S, Richens A. Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol. 1982;13:553-60.
33) Laegreid L, Kyllerman M, Hedner T, Hagberg B, Viggedahl G. Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy. Neuropediatrics. 1993;24:88-92.
34) Product Information. Tegretol (carbamazepine). Novartis Pharmaceuticals. 2002.
35) Cerner Multum, Inc. UK Summary of Product Characteristics.
36) Product Information. Lybalvi (olanzapine-samidorphan). Alkermes, Inc. 2021.
37) Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993;53:84-8.
38) Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry. 1989;146:278.
39) Hadley A, Cason MP. Mania resulting from lithium-fluoxetine combination. Am J Psychiatry. 1989;146:1637-8.
40) Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-13.
41) Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry. 1989;146:1515.
42) Muly EC, McDonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry. 1993;150:1565.
43) Product Information. Zoloft (sertraline). Roerig Division. 2001.
44) Product Information. Prozac (fluoxetine). Dista Products Company. 2001